Arifa Aziz¹*, Adeeba Zaki² and Iffat Shehzad³

¹Staff Medical Officer, Supervisor at Day Care Oncology, Department of Oncology, Aga Khan University Hospital, Pakistan
²Senior Instructor, Medical Oncologist, Department of Oncology, Aga Khan University Hospital, Pakistan
³Medical Officer, Department of Oncology, Aga Khan University Hospital, Pakistan

*Corresponding Author: Arifa Aziz, Staff Medical Officer, Supervisor at Day Care Oncology, Department of Oncology, Aga Khan University Hospital, Pakistan.

Received: April 10, 2023; Published: May 10, 2023

Abstract

Background: Trastuzumab is a monoclonal antibody that inhibits tumor cell growth by binding to the extracellular region of the HER 2 protein and blocking the signalling pathway with overexpressed HER 2 positive breast cancer patients. Mostly presented at an advanced stage and have a significantly shortened disease-free and overall survival. Our objective is to find out the frequency of cardiac toxicity with trastuzumab given subcutaneous,

Method: Questionnaire form for audit was developed which included questions on shortness of breath, palpitation, edema feet, chest pain and echocardiogram report. Trastuzumab is given through subcutaneous route at dose of 600 mg and eechocardiogram monitored at every 3 months. Data collected from April 2022 till August 2022.

Result: Fifty patients’ data was collected, out of theses only one patient developed shortness of breath. and chest pain. Two echocardiograms’ reports were checked at an interval of three months, both showing normal ejection fraction (55% to 60%).

Conclusion: Cardiac toxicity is minimal with trastuzumab given subcutaneously.

 Keywords: Transtuzumab; Cardiac toxicity; Hypertension

References

1. Chen J., et al. “Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer”. Journal of the American College of Cardiology 60 (2012): 2504-2512.
2. Sandor A., et al. “Endothelial dysfunction as a determinant of trastuzumab-mediated cardiotoxicity in patients with breast cancer”. Anticancer Research 34 (2014): 1147-1151.
3. Sendur MAN., et al. “Cardiotoxicity of novel HER2-targeted therapies”. Current Medical Research and Opinion 29 (2013): 1015-1024.
4. Albanell J., et al. “Trastuzumab in small tumours and in elderly women”. Cancer Treatment Reviews 40 (2014): 41-47.
5. Gonzalez-Angulo AM., et al. “High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller”. Journal of Clinical Oncology 27 (2009): 5700-5706.
6. Beser AR., et al. “HER-2, TOP2A and chromosome 17 alterations in breast cancer”. Pathology and Oncology Research 13 (2007): 180-185.
7. Witton CJ., et al. “Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer”. Journal of Pathology 200 (2003): 290-297.
8. Morrison G., et al. “Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance”. Breast Cancer Research and Treatment 144 (2014): 263-272.
9. Jiang Z and Zhou M. “Neuregulin signalling and heart failure”. Current Heart Failure Reports 7 (2010): 427.
10. Demissei BG., et al. “Cardiovascular function phenotypes in response to cardiotoxic breast cancer therapy”. Journal of the American College of Cardiology 73 (2019): 248-249.
11. Spector NL and Blackwell KL. “Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer”. Journal of Clinical Oncology 27 (2009): 5838-5847.
12. Kirkham AA., et al. “Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trial”. European Heart Journal - Cardiovascular Pharmacotherapy (2021).
13. Zamorano JL., et al. “2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines”. Kardiologia Polska 74 (2016): 1193-233.
14. Seidman A., et al. “Cardiac dysfunction in the trastuzumab clinical trials experience”. Journal of Clinical Oncology 20 (2002): 1215-1221.
15. Karaca M., et al. “Ventricular bigeminal rhythm associated with trastuzumab: a potential cardiac side effect”. Journal of Cancer Research and Therapeutics 14 (2018): S536-537.
16. Advani PP., et al. “Long-term cardiac safety analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial”. Journal of Clinical Oncology 34 (2016): 581-587.

Citation

Citation: Arifa Aziz., et al. “Audit on Incidence of Trastuzumab Induced Cardiac Toxicity in Day Care Oncology at a Tertiary Care Hospital, Karachi, Pakistan". Acta Scientific Pharmaceutical Sciences 7.6 (2023): 14-17.

Copyright

Copyright: © 2023 Arifa Aziz., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.